

119TH CONGRESS
2D SESSION

S. 5237

To require the Director of the National Institute of Allergy and Infectious Diseases to award a competitive grant for the Antibiotic Resistance Leadership Group for the purpose of facilitating a clinical research network on antibiotic resistance, and for other purposes.

IN THE SENATE OF THE UNITED STATES

AUGUST 4, 2026

Ms. HASSAN (for herself and Mr. MARSHALL) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

A BILL

To require the Director of the National Institute of Allergy and Infectious Diseases to award a competitive grant for the Antibiotic Resistance Leadership Group for the purpose of facilitating a clinical research network on antibiotic resistance, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Stop Superbugs Act”.

1 **SEC. 2. FUNDING FOR ANTIBIOTIC RESISTANCE CLINICAL**
2 **RESEARCH.**

3 (a) IN GENERAL.—The Director of the National In-
4 stitute of Allergy and Infectious Diseases shall award a
5 competitive grant for the Antibiotic Resistance Leadership
6 Group for the purpose of facilitating a clinical research
7 network on antibiotic resistance, which shall include fo-
8 cuses on—

9 (1) supporting rapid recruitment of clinical trial
10 participants;

11 (2) conducting clinical trial recruitment out-
12 reach in community settings;

13 (3) supporting the pairing of diagnostic and
14 pharmaceutical innovations during clinical trials;
15 and

16 (4) developing patient-reported outcomes in
17 clinical studies.

18 (b) AUTHORIZATION OF APPROPRIATIONS.—There is
19 authorized to be appropriated to the Director of the Na-
20 tional Institute of Allergy and Infectious Diseases such
21 sums as may be necessary to carry out subsection (a).

○